Projects per year
Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.
- 1 Similar Profiles
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Medicine & Life Sciences
Peripheral Nervous System Diseases
Medicine & Life Sciences
Eosinophilia-Myalgia Syndrome
Medicine & Life Sciences
Intravenous Immunoglobulins
Medicine & Life Sciences
Polyneuropathies
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Immunoglobulins
Medicine & Life Sciences
Epidemic Pleurodynia
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2014 2022
A Phase 1b Study to Evaluate the Safety, Tolerability and Drug-Drug Interactions of ANX005 and Intravenous Immunoglobulin (IVIg) in Subjects with Guillain-Barre Syndrome
10/1/19 → 9/30/22
Project: Research project
Guillain-Barre Syndrome
Intravenous Immunoglobulins
Drug Interactions
Safety
Pharmaceutical Preparations
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of RVT-2401 in MyastheniaGravis Patients
1/1/19 → 12/31/21
Project: Research project
Myasthenia Gravis
Placebos
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intravenous Immunoglobulins
Hand Strength
Therapeutics
Diabetic Neuropathies
Peripheral Nervous System Diseases
Multicenter Studies
Placebos
Safety
Immunoglobulins
Placebos
Safety
Therapeutics
Hizentra
Research Output 2000 2020
Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?
Allen, J. A., Gelinas, D. F., Freimer, M., Runken, M. C. & Wolfe, G. I., Jan 15 2020, In : Journal of the Neurological Sciences. 408, 116497.Research output: Contribution to journal › Article
Open Access
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intravenous Immunoglobulins
Immunoglobulins
Therapeutics
Stretch Reflex
1
Citation
(Scopus)
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies
on Behalf of the PRIMA Trial Investigators and the PATH Study Group, Mar 2019, In : Journal of the Peripheral Nervous System. 24, 1, p. 48-55 8 p.Research output: Contribution to journal › Article
Open Access
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Polyneuropathies
Intravenous Immunoglobulins
Safety
Drug-Related Side Effects and Adverse Reactions
1
Citation
(Scopus)
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study
on behalf of the PATH study group, Mar 2019, In : Journal of the Peripheral Nervous System. 24, 1, p. 72-79 8 p.Research output: Contribution to journal › Article
Open Access
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Polyneuropathies
Intravenous Immunoglobulins
Random Allocation
Therapeutics
1
Citation
(Scopus)
Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis
Breiner, A., Bourque, P. R. & Allen, J. A., Aug 2019, In : Muscle and Nerve. 60, 2, p. 180-183 4 p.Research output: Contribution to journal › Article
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Cerebrospinal Fluid Proteins
Reference Values
Diagnostic Errors
Cohort Studies
4
Citations
(Scopus)
231st ENMC International Workshop:: International Standard for CIDP Registry and Biobank, Naarden, The Netherlands, 12–14 May 2017
participants of the 231st ENMC workshop, Feb 2018, In : Neuromuscular Disorders. 28, 2, p. 178-184 7 p.Research output: Contribution to journal › Article
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Netherlands
Registries
Education